PubMed · 11609113
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
L J Vandewiele. 1995. [Not Available].. https://pubmed.ncbi.nlm.nih.gov/11609113/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Since 1984, the World Health Organization (WHO) European Region has had targets for reducing the burden of a number of communicable diseases. While some countries have already met the targets for interrupting indigenous measles transmission and for reducing the incidence of congenital rubella syndrome to <1 case per 100,000 births, most have not. The cultural and economic diversity of the region present a number of challenges that must be overcome before the regional targets are met. These include social factors, political will, economic costs associated with supplementary campaigns, and more effective communication with health professionals and the public on the benefits and risks associated with immunization. Most WHO European Region member states are expected to use combined measles-mumps-rubella vaccine within the next 5 years. Consultation within the region is occurring on a strategic plan to meet the targets by 2010.
Flowabilities of six commercially available, direct compression excipients, Emcompress, Fujicalin, Starch 1500, Avicel PH-102, Tablettose 80, and Tablettose 100 were examined according to the technical procedure described in the current European Pharmacopoeia, and with a Sotax Flow Tester. Results revealed unfavourable properties for Fujicalin compared to other substances. Fujicalin, however, appeared macroscopically to be of extremely pronounced free-flowing properties. This contradiction was studied in more detail, proposing to express powder flow in terms of volume per time unit rather than mass per time unit (volume-flowability).
Explore the source record for details and available documents.